4507:TYO
Shionogi & Co Ltd
2Â 744,50Â JPÂ¥
arrow_downward
-0,88%(-24,50) 1K
9-okt, 15:30:00 (GMT+9) · JPY
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto4507 tikeri uchun statistika yaratilmoqda...
Ochish
2Â 758Â JPÂ¥
Yuqori
2Â 778Â JPÂ¥
Past
2Â 734Â JPÂ¥
Bozor kapitali
2,44Â trln
Oʻrtacha hajm
2,93Â mln
Hajmi
3,31Â mln
Dividend
2,59%
Choraklik dividendlar
18Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
8,86
52 haftalik eng yuqori
3Â 758Â JPÂ¥
52 haftalik eng past
2Â 392Â JPÂ¥
Aksiya boʻyicha daromad
310Â JPÂ¥
Muomaladagi aksiyalar
314,50Â mln
Xodimlar soni
6Â ming
Ochish
2Â 758Â JPÂ¥
Yuqori
2Â 778Â JPÂ¥
Past
2Â 734Â JPÂ¥
Bozor kapitali
2,44Â trln
Oʻrtacha hajm
2,93Â mln
Hajmi
3,31Â mln
Dividend
2,59%
Choraklik dividendlar
18Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
8,86
52 haftalik eng yuqori
3Â 758Â JPÂ¥
52 haftalik eng past
2Â 392Â JPÂ¥
Aksiya boʻyicha daromad
310Â JPÂ¥
Muomaladagi aksiyalar
314,50Â mln
Xodimlar soni
6Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance UK
·
1 kun oldin
Shionogi (TSE:4507) Weighs IntraBio Acquisition, Is The Stock A Bargain?
Simply Wall Street
·
1 kun oldin
Shionogi (TSE:4507) Weighs IntraBio Deal, Is The Stock Undervalued?
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Shionogi & Co Ltd haqida